CN1125607A - Manufacture method of liquid for treatment of cerebrovascular disease - Google Patents
Manufacture method of liquid for treatment of cerebrovascular disease Download PDFInfo
- Publication number
- CN1125607A CN1125607A CN 95105651 CN95105651A CN1125607A CN 1125607 A CN1125607 A CN 1125607A CN 95105651 CN95105651 CN 95105651 CN 95105651 A CN95105651 A CN 95105651A CN 1125607 A CN1125607 A CN 1125607A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- treatment
- medicinal liquid
- percolation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The liquid medicine for curing cerebrovascular disease is prepared from 16 Chinese-medicinal ingredients such as Chuan-xiong rhizome, red sage root, spatholobus stem, rehmannia root, Chinese angelica root, etc. through removing impurities, drying in air, low-temp baking, crushing, wetting, laying aside for 1.5-2.5 hr, immersing in spirit for over 48 hr, filter, dissolving borneol in liquid, laying aside for 7 days, filter and bottling.
Description
The present invention relates to medicine, be specially the method for production and the medicine thereof of Chinese medicine.
The medicine of treatment coronary heart disease, angina pectoris, cerebral embolism has a variety of at present.But curative effect is not very good.
The object of the present invention is to provide a kind of headache, chest pain that can be used for blood circulation promoting and blood stasis dispelling, dredge the meridian passage, stagnation of blood stasis, with the Chinese medicine preparation of numb limbs and tense tendons disease of a specified duration.
The object of the present invention is achieved like this: by 10-11 parts of Rhizoma Chuanxiongs, 9-10 parts of Radix Salviae Miltiorrhizaes, 9-10 parts of Caulis Spatholobis, 7-8 parts in the Radix Rehmanniae, 7-8 parts of Radix Angelicae Sinensis, 6.0-6.5 parts of Fructus Crataegis, 6.0-6.5 parts of Radix Paeoniae Rubra, 6.0-6.5 parts of Radix Puerariaes, 6.0-6.5 parts of Radix Ginsengs, 5.3-5.5 parts of Cortex Moutans, 4.8-5.2 parts of Hirudos, 4.6-5.0 parts of Rhizoma Acori Gramineis, 4.3-4.5 parts of Pheretimas, 3.8-4.2 parts of Radix Notoginseng, 2.5-3.0 parts of Spina Gleditsiae, 8.15-0.2 part of composition of Borneolum Syntheticum, with above component (except the Borneolum Syntheticum) washing decontamination, naturally after drying, oven drying at low temperature, be ground into coarse powder, after moistening, placed 1.5-2.5 hours, pack in the percolation jar, adding Chinese liquor covers coarse powder and soaks greater than after 48 hours, carry out percolation, the medicinal liquid that percolation comes out adds Borneolum Syntheticum and is stirred to molten entirely, static greater than after 7 days, filter bottling, in order to oral.
The invention has the advantages that 20 examples of taking medicine of the present invention are diagnosed as the ischemia apoplexy patient, 1 month course of treatment, obvious effective rate 35%, effective percentage 50%, inefficiency 15% total effective rate 85%.
Embodiments of the invention are as follows:
Be diagnosed as ischemia apoplexy patient 40 examples through clinical and CT, the course of disease 2-12 months, male 26 examples, women 14 examples, year makes 39-70 years old, and average year makes 55.2 years old, is divided into each 20 example of observation group and matched group at random.
Medicine and Therapeutic Method: observation group selects for use medicinal liquid 20ml of the present invention oral, and three times on the one, one month course of treatment.The Radix Salviae Miltiorrhizae oral liquid 10ml that matched group selects for use Shanghai first pharmaceutical factory to produce is oral, and three times on the one, be one month the course of treatment.Observation index, 1, total effective rate; 2, subjective symptoms; 3, traditional Chinese medical science picture of the tongue; 4, myodynamic examination; 5, examination of nail fold microcirculation; 6, blood examination; 7, lipid examination; 8, liver function, kidney merit.
Therapeutic outcome:
1, total effective rate (seeing Table 1), produce effects person's symptom is obviously improved, every inspection recover normal or the improvement amplitude greater than 30%; Responder's doing well,improving, every inspection improve amplitude greater than 10%, and do not recover normal person.
Table 1 medicinal liquid treatment of the present invention ischemia apoplexy total effective rate
| Produce effects example effectively the invalid routine total effective rate P of example (%) (%) (%) (%) | |
| Observation group's 20 routine matched group 20 examples | 7(35)???10(50)??3(15)????85 ????????????????????????????＞0.05 5(25)????9(45)??6(30)????70 |
2, subjective symptoms curative effect (seeing Table 2)
The conscious card shape of table 2 medicinal liquid treatment of the present invention ischemia apoplexy improves to be observed
| Observation group treats precedent and treats back improvement rate % improvement example | Matched group is treated precedent and is treated back improvement rate % improvement example | Two groups of improvement rates compare the P value | |
| The dizziness headache shortness of breath and palpitation | ????15????9????60 ????12???11????92 ?????9????5????56 | ????16????8????50 ????13????8????62 ?????7????3????57 | ????＞0.05 ????＜0.05 ????＞0.05 |
Observation group treats back headache improvement rate and obviously is better than matched group (P＜0.05), illustrates that medicinal liquid of the present invention and Radix Salviae Miltiorrhizae oral liquid are improving aspect the ischemia apoplexy symptom all effective in curely, is improving aspect the headache, and medicinal liquid of the present invention is evident in efficacy.
3, picture of the tongue changes curative effect (seeing Table 3)
Table 3 medicinal liquid treatment of the present invention ischemia apoplexy patient picture of the tongue changes to be observed
| Observation group treats precedent and treats back improvement rate % improvement example | Matched group is treated precedent and is treated back improvement rate % improvement example | Two groups of improvement rates compare the P value | |
| Purple dark ecchymosis is red, etc. Tianjin | ????10????9?????90 ?????5????4?????80 ?????5????3?????60 | ???11????7?????63 ????4????2?????50 ????5????3?????60 | ??＜0.05 ??＜0.05 ??＞0.05 |
The purple dark tongue in back is treated by observation group and blood stasis tongue improvement rate obviously is better than matched group (P＜0.05), illustrates that medicinal liquid of the present invention has better curative effect aspect the blood stasis tongue improving.
4, muscular strength treatment curative effect (seeing Table 4)
Table 4 medicinal liquid treatment of the present invention ischemia apoplexy patient muscular strength improves the treatment muscular strength improvement of observation observation group has notable difference (P＜0.05) than matched group.
| Average muscular strength improves the progression significance test | |
| Observation group's 20 routine matched group 20 examples | ????2.07＋0.08 ???????????????????????P＜0.05 ????1.58＋0.10 |
5, examination of nail fold microcirculation (seeing Table 5)
The microcirculatory influence of table 5 medicinal liquid treatment ischemia apoplexy nail fold of the present invention
| Blood flow rate Hmls X ± SD | Special pipe loop rate % X ± SD | Microcirculation blood stasis rate % X ± SD P | |
| After (20 example) treated before observation group was treated | 268±44 ????????＜0.05 323±51 | 55±12 ??????＜0.01 28±11 | 59±13 ??????????＜0.01 19±17 |
| After (20 example) treated before matched group was treated | 270±48 ????????＜0.05 322±68 | 58±15 ??????＜0.05 33±10 | 53±14 ??????????＜0.05 18±12 |
Before and after the observation group treatment nail fold microcirculation blood flow velocity, special pipe loop rate, microcirculation blood stasis rate relatively there were significant differences (P＜0.05＜0.01) wherein blood flow rate improve 321%, special pipe loop rate reduces 3.48%, microcirculation blood stasis rate has reduced by 67%, with the matched group contrast, though there is not significant difference (P＞0.05)
6, blood examination (seeing Table 6)
The hemorheological influence of table 6 medicinal liquid treatment ischemia apoplexy of the present invention
| The low ratio of viscosities X ± SD P that cuts of whole blood | Plasma viscosity is than X ± SD P | White former mg X of fiber dawn ± SD P | |
| After (20 example) treated before observation group was treated | 7.18±0.36 ??????????＜0.05 5.37±0.41 | 1.83±0.11 ??????????＜0.05 1.55±0.09 | 354±32 ????????＜0.01 264±33 |
| After (20 example) treated before contrast was given and treated | 7.12±0.54 ??????????＜0.05 5.39±0.52 | 1.84±0.13 ??????????＜0.05 1.57±0.08 | 358±40 ????????＜0.05 279±35 |
The low viscosity, plasma viscosity, fiber dawn white source content of cutting of whole blood has obvious reduction (P＜0.05＜0.01) before and after the observation group treatment, wherein whole blood is low cuts ratio of viscosities and has reduced by 25%, the plasma viscosity ratio has reduced by 15%, and the fiber dawn is white has formerly reduced by 25%, does not relatively have significant difference with matched group.
7, blood fat curative effect (seeing Table 7)
The influence of table 7 medicinal liquid treatment of the present invention ischemia apoplexy blood fat
| Cholesterol mmo//l X ± SD P | Glycerol three vinegar mmo//l X ± SD P | White cholesterol mmo//l X of high density fat dawn ± SD P | |
| After (20 example) treated before observation group was treated | 5.26±0.71 ????????＜0.05 4.30±0.91 | 2.14±0.48 ????????＜0.05 1.81±0.35 | 0.89±0.25 ?????????????＞0.05 1.16±0.30 |
| After (20 example) treated before contrast was given and treated | 5.16±0.93 ????????＞0.05 4.65±1.03 | 2.09±0.41 ????????＞0.05 1.92±0.38 | 0.85±0.23 ?????????????＜0.05 1.18±0.29 |
Cholesterol, triglyceride have obvious reduction (P＜0.05) before and after observation group's treatment, have descended 18% and 15% respectively, and white cholesterol of high density fat dawn has obvious rising (P＜0.05), has raise 13%.Compare with matched group, though there is not significant difference (P＞0.05), every index is improved all the trend that is better than matched group.
8, liver function, kidney merit are checked; Blood urea nitrogen, GPT, TTT, R-GT, Iod R are measured all in normal range before observation group and matched group are treated, after the treatment.
From above example as can be known the present invention ischemia apoplexy patient's subjective symptoms and picture of the tongue are improved better effects are arranged, especially to headache companion blood stasis picture of the tongue person better effects if; Myodynamia recovery to the ischemia apoplexy patient has better effect; The nail fold microcirculation is changed, and hemorheology changes, metabolism disorder of blood lipid all has a better role; The treatment ischemia apoplexy always effectively is 85%; Liver function, kidney merit through one month clinical observation, patient all do not have obvious change, do not see other untoward reaction, application safety.Embodiments of the invention attached second hospital clinical of the Heilongjiang Province college of traditional Chinese medicine test that disease card draws.
Claims (1)
1, a kind of treatment cerebrovascular disease medicinal liquid method for production, it is characterized in that: by 10-11 parts of Rhizoma Chuanxiongs, 9-10 parts of Radix Salviae Miltiorrhizaes, 9-10 parts of Caulis Spatholobis, 7-8 parts in the Radix Rehmanniae, 7-8 parts of Radix Angelicae Sinensis, 6.0-6.5 parts of Fructus Crataegis, 6.0-6.5 parts of Radix Paeoniae Rubra, 6.0-6.5 parts of Radix Puerariaes, 6.0-6.5 parts of Radix Ginsengs, 5.3-5.5 parts of Cortex Moutans, 4.8-5.2 parts of Hirudos, 4.6-5.0 parts of Rhizoma Acori Gramineis, 4.3-4.5 parts of Pheretimas, 3.8-4.2 parts of Radix Notoginseng, 2.5-3.0 parts of Spina Gleditsiae, 0.15-0.2 part of composition of Borneolum Syntheticum, with above component (except the Borneolum Syntheticum) washing decontamination, naturally after drying, oven drying at low temperature, be ground into coarse powder, after moistening, placed 1.5-2.5 hours, pack in the percolation jar, adding Chinese liquor covers coarse powder and soaks greater than after 48 hours, carry out percolation, the medicinal liquid that percolation comes out adds Borneolum Syntheticum and is stirred to molten entirely, static greater than after 7 days, filter bottling, in order to oral.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 95105651 CN1125607A (en) | 1995-06-09 | 1995-06-09 | Manufacture method of liquid for treatment of cerebrovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 95105651 CN1125607A (en) | 1995-06-09 | 1995-06-09 | Manufacture method of liquid for treatment of cerebrovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1125607A true CN1125607A (en) | 1996-07-03 |
Family
ID=5075558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 95105651 Pending CN1125607A (en) | 1995-06-09 | 1995-06-09 | Manufacture method of liquid for treatment of cerebrovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1125607A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1070375C (en) * | 1997-09-15 | 2001-09-05 | 武汉博海生物工程有限公司 | Emulsion for lowering blood-lipid, and method for preparing same |
| CN1943642B (en) * | 2006-10-18 | 2010-09-08 | 北京中医药大学 | Preparing method for a kind of medicinal composition and its effective parts and active ingredients |
| CN103690717A (en) * | 2013-11-29 | 2014-04-02 | 程力 | Traditional Chinese medicine preparation for treating stroke |
| CN104367896A (en) * | 2014-09-30 | 2015-02-25 | 刘庆春 | Pharmaceutical composition for treating qi deficiency and blood stasis-type apoplexy and preparation method thereof |
| CN113925890A (en) * | 2020-06-29 | 2022-01-14 | 香港大学 | Extraction method of caulis spatholobi extract, caulis spatholobi extract and application thereof |
-
1995
- 1995-06-09 CN CN 95105651 patent/CN1125607A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1070375C (en) * | 1997-09-15 | 2001-09-05 | 武汉博海生物工程有限公司 | Emulsion for lowering blood-lipid, and method for preparing same |
| CN1943642B (en) * | 2006-10-18 | 2010-09-08 | 北京中医药大学 | Preparing method for a kind of medicinal composition and its effective parts and active ingredients |
| CN103690717A (en) * | 2013-11-29 | 2014-04-02 | 程力 | Traditional Chinese medicine preparation for treating stroke |
| CN104367896A (en) * | 2014-09-30 | 2015-02-25 | 刘庆春 | Pharmaceutical composition for treating qi deficiency and blood stasis-type apoplexy and preparation method thereof |
| CN104367896B (en) * | 2014-09-30 | 2017-10-03 | 刘庆春 | A kind of pharmaceutical composition for treating Qi deficiency blood stasis type apoplexy and preparation method thereof |
| CN113925890A (en) * | 2020-06-29 | 2022-01-14 | 香港大学 | Extraction method of caulis spatholobi extract, caulis spatholobi extract and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1682989A (en) | Chinese medicine for treating depression | |
| CN102688327B (en) | Medicine composition of damp itch lotion and preparation method of medicine composition | |
| CN1125607A (en) | Manufacture method of liquid for treatment of cerebrovascular disease | |
| CN114010709A (en) | External traditional Chinese medicine ointment for treating myopia and preparation method thereof | |
| CN1861183A (en) | Traditional Chinese medicine capsule for treating mammary gland diseases | |
| CN1137389A (en) | Method for preparation of medicine for external use and its emulsion for curing acne | |
| CN1290572C (en) | External use Chinese medicinal preparation for treating alopecia and its preparation method | |
| CN113041324A (en) | Traditional Chinese medicine composition for treating qi deficiency and blood stasis type diabetic nephropathy and preparation method thereof | |
| CN1127344C (en) | Oral pill for curing diabetes and its complication | |
| CN1294982C (en) | Medication for curing alopecia | |
| CN1117384A (en) | Traditional Chinese medicinal prescription (capsule series) for treating cardiovascular disease or cerebrovascular disease and method for mfg. same | |
| CN1063078C (en) | Chinese herbal decoction as oral liquid and its preparation and application | |
| CN1059117C (en) | Katsutoxin pill for tumor and preparing method thereof | |
| CN105412731A (en) | Ointment for treating skin pruritus and preparing method thereof | |
| CN1788764A (en) | Traditional Chinese medicine formulation for improving pulmonary fibrosis | |
| CN1048635C (en) | A tincture for the treatment of ichthyosis | |
| CN1048638C (en) | Xifukang Chinese herb medicine compound preparation for silicosis and its preparing method | |
| CN1245197C (en) | Chinese medicine preparation for treating coronary heart disease and viral myocarditis | |
| CN1846733A (en) | Externally applied skin care liquid extracted from plant and its prepn process | |
| CN1050298C (en) | Traditional Chinese medicine powder for bone-setting, and method for preparing same | |
| CN115414295B (en) | Compound plant acne-removing mite-inhibiting composition and preparation method and application thereof | |
| CN1397329A (en) | Medicine for treating acne and its preparing process | |
| CN1130081A (en) | Recipe for medicinal pillow core and its producing method | |
| CN1122509C (en) | Medicinal patch for treating hepatism | |
| CN106692453B (en) | Chinese herbal medicine composition for treating Parkinson's disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |